How confidential trial negotiations and agreements between the Food and Drug Administration and sponsors marginalize local institutional review boards, and what to do about it.
作者信息
Mann Howard
机构信息
School of Medicine, University of Utah, USA.
出版信息
Am J Bioeth. 2006 May-Jun;6(3):22-4; discussion W49-50. doi: 10.1080/15265160600685663.
PMID:16754442
Abstract
摘要
相似文献
1
How confidential trial negotiations and agreements between the Food and Drug Administration and sponsors marginalize local institutional review boards, and what to do about it.
Am J Bioeth. 2006 May-Jun;6(3):22-4; discussion W49-50. doi: 10.1080/15265160600685663.
2
Rules is rules.
Am J Bioeth. 2006 May-Jun;6(3):40-1; discussion W49-50. doi: 10.1080/15265160600685929.
3
Acting out of ethics: what the open letter asks.
Am J Bioeth. 2006 May-Jun;6(3):41-3; discussion W49-50. doi: 10.1080/15265160600685937.
4
Unproven or unsatisfactory versus equipoise in emergency research with waived consent.
Am J Bioeth. 2006 May-Jun;6(3):44-5. doi: 10.1080/15265160600685952.
5
Clinical trial protocols: agreements between the FDA and industrial sponsors.
Lancet. 2002 Nov 2;360(9343):1345-6. doi: 10.1016/S0140-6736(02)11415-2.
6
Americans should not be on a game show in U.S. emergency rooms and ambulances.
Am J Bioeth. 2010 Oct;10(10):9-10. doi: 10.1080/15265161.2010.525165.
7
Blood, sweat and tears.
Am J Bioeth. 2006 May-Jun;6(3):1-2. doi: 10.1080/15265160600781488.
8
An open letter to institutional review boards considering Northfield Laboratories' PolyHeme trial.
Am J Bioeth. 2006 May-Jun;6(3):18-21. doi: 10.1080/15265160600685580.
9
Emergency research and consent: keeping the exception from undermining the rule.
Am J Bioeth. 2006 May-Jun;6(3):36-7; discussion W49-50. doi: 10.1080/15265160600685879.
10
Artificial-blood study has critics seeing red.
Chron High Educ. 2006 Jun 16;52(41):A17.
Zotero 插件